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Abstract
Background: Barrett's mucosa is the precursor of esophageal adenocarcinoma. The molecular
mechanisms behind Barrett's carcinogenesis are largely unknown. Experimental models of
longstanding esophageal reflux of duodenal-gastric contents may provide important information on
the biological sequence of the Barrett's oncogenesis.
Methods: The expression of CDX2 hox-gene product was assessed in a rat model of Barrett's
carcinogenesis. Seventy-four rats underwent esophago-jejunostomy with gastric preservation.
Excluding perisurgical deaths, the animals were sacrificed at various times after the surgical
treatment (Group A: <10 weeks; Group B: 10–30 weeks; Group C: >30 weeks).
Results:  No Cdx2 expression was detected in either squamous epithelia of the proximal
esophagus or squamous cell carcinomas. De novo Cdx2 expression was consistently documented
in the proliferative zone of the squamous epithelium close to reflux ulcers (Group A: 68%; Group
B: 64%; Group C: 80%), multilayered epithelium and intestinal metaplasia (Group A: 9%; Group B:
41%; Group C: 60%), and esophageal adenocarcinomas (Group B: 36%; Group C: 35%). A trend
for increasing overall Cdx2 expression was documented during the course of the experiment (p =
0.001).
Conclusion: De novo expression of Cdx2 is an early event in the spectrum of the lesions induced
by experimental gastro-esophageal reflux and should be considered as a key step in the
morphogenesis of esophageal adenocarcinoma.
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Background
In the homeobox gene family, the caudal-related CDX2
gene encodes for an intestine-specific transcription factor
involved in both cell turnover and intestinal differentia-
tion [1]. Nuclear immunostain for Cdx2 is restricted to the
native intestinal epithelia and its de novo expression is
considered as suitable marker of a newly achieved intesti-
nal commitment [2,3].
Barrett's esophagus (BE) is defined as replacement of the
native esophageal squamous epithelium by columnar
(intestinalized) mucosa [4-6]. Longstanding exposure of
the squamous esophageal epithelium to gastric reflux is a
primary risk factor for columnar metaplasia, which is con-
sistently considered as precursor of esophageal adenocar-
cinoma (Ac) [7,8].
Esophageal Ac is the final step in a sequence of pheno-
typic changes that include long-standing esophagitis,
columnar cell metaplasia, and non-invasive neoplasia
(NiN). The molecular derangements occurring in each of
these phenotypic changes are largely unknown and they
involve both genetic and chromosomal instability [9,10].
More information on such molecular changes is crucial in
any strategy of primary prevention of Barrett's Ac [11-14].
In humans, both practical and ethical limitations prevent
any sequential exploration of the cascade of Barrett's Ac,
so experimental models are used to characterize the bio-
logical alterations leading to neoplastic transformation
[15-31].
In this experimental study, the expression of Cdx2 protein
was tested over the whole spectrum of phenotypic lesions
detected in a surgical murine model of esophago-gas-
troduodenal anastomosis (EGDA) resulting in longstand-




An esophago-gastroduodenal anastomosis was performed
on 74 eight-week-old male Wistar Han rats (Charles River,
Lecco, Italy), as described elsewhere [19,21-24,29]. Before
surgery, the animals were kept under standard laboratory
conditions. In brief, a 1.5 cm side-to-side surgical EGDA
was created between the first duodenal loop and the gas-
tro-esophageal junction, about 3 cm distal to Treitz's liga-
ment, with accurate mucosa-to-mucosa opposition
(Figure 1), so that duodenal and gastric contents flowed
back into the esophagus. Unlike other models, this "Kum-
agai-Hattori" model preserves the animal's normal stom-
ach function and nutritional status [19,21,22].
Postoperatively, the animals had free access to water and
food. No treatments with any known carcinogen were
applied.
Ten of the 74 rats died (mainly of respiratory complica-
tions) within 7 days after surgery and were not consid-
ered. As in already published experimental models, the
animals were sacrificed at different times after surgery (i.e.
Group A [22 rats] after <10 weeks [range = 3–9.9], Group
B [22 rats] after 10–30 weeks [range = 10–29.7], and
Group C [20 rats] after >30 weeks [range = 31–54])
[19,21,22,27,28].
This study was approved by the Institutional Animal Care
Committee of the University of Padova. All procedures
were performed in accordance to the Italian law on the use
of experimental animals (DL n. 116/92 art. 5) and accord-
ing to the "Guidelines on the Care and Use of Laboratory
Animals" (NIH publication 85–93, revised in 1985).
Pathology
Immediately after death, the thoracic and abdominal cav-
ities were examined and the esophagus, stomach, and
jejunum were excised en bloc. The esophagus was opened
longitudinally through the dorsal wall. With the mucosal
surface uppermost, the margins of the specimen were
fixed to a cork plate with pins. Gross specimens were fixed
in 10% neutral-buffered formalin for 24 hours. All speci-
mens were examined grossly (see gross pathology) and cut
serially (2–3 mm thick coronal sections). The tissue sam-
ples were routinely processed. Tissue sections 4 μm thick
were obtained from paraffin blocks and stained with Hae-
matoxylin & eosin. Lung, liver, kidney and spleen tissues
were also collected for histological assessment. Two expe-
rienced gastrointestinal pathologists (GI & MF) reviewed
all the slides.
Histological findings in the squamous epithelium lesions
were grouped into 5 main categories (Table 1, Figure 2)
[16,18,25]: (1) non-ulcerative esophagitis; (2) ulcers
(always associated with inflammation and granulation
tissue); (3) regenerative-hyperplastic (also polypoid)
lesions; (4) multilayered epithelium (MLE) and/or intes-
tinal metaplasia within squamous epithelium; and (5)
carcinomas (distinguishing esophageal adenocarcinoma
[Ac] from squamous cell esophageal cancer [SCC]).
Non-ulcerative esophagitis was defined as sub-epithelial
inflammatory infiltrate, generally coexisting with intraep-
ithelial leukocytes; epithelial micro-erosions were arbi-
trarily included in this category.
Ulcers (defined as the complete loss of the mucosal layer
with muscle exposure) always coexisted with granulationJournal of Experimental & Clinical Cancer Research 2009, 28:108 http://www.jeccr.com/content/28/1/108
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tissue and hyperplastic-regenerative changes of the sur-
rounding epithelium.
Hyperplastic lesions were defined as thickening of the
squamous epithelium (sometimes hyperkeratotic) with
no cellular atypia. Regenerative lesions were assessed in
terms of the increased length of the papillae in the lamina
propria (>70% of mucosal thickness), also coexisting with
hyperplasia of the proliferative compartment (>20% of
the mucosal thickness) [16,18,25].
Metaplastic intestinalization was defined as the presence
of both columnar epithelia and goblet cells [16,18,25].
Multilayered epithelium (MLE) is a hybrid epithelium in
which both squamous and columnar epithelia coexist
("protometaplasia"); consistently with its phenotype,
MLE expresses cytokeratins of both squamous and colum-
nar differentiation [32].
Cancers were distinguished according to their histotype.
Squamous cell carcinoma consisted in a neoplastic
growth of squamous epithelia with different grades of dif-
ferentiation. Adenocarcinoma consisted of atypical tubu-
lar/cystic glands with abundant extra-cellular mucins
(Figure 1). Consistently with previous studies [18,27,29],
we did not consider an autonomous group of "atypical"
epithelial lesions. In fact, such phenotypical alterations
are inconsistently described by the current international
literature and their negligible prevalence in our study rep-
resents the rationale of including them among non-cancer
lesions.
Immunohistochemistry (IHC)
Cdx2 immunostain (anti-mouse-Cdx2 antibody, dilution
1:10; BioGenex Laboratories Inc., San Ramon, CA) was
applied on 4-μm tissue sections. In all cases, a standard-
ized ABC method was used, implemented on the Ventana
Benchmark XT system (Touchstone, AZ). Appropriate
positive (mouse colon) and negative (mouse spleen) con-
trols were always run concurrently.
Cdx2 IHC expression was assessed negative (no immu-
nostaining or sparse Cdx2-stained nuclei in less than 5%
of the cells) or positive (nuclear immunoreaction in 5%
or more of the cells).
Statistical analysis
Differences seen during the course of the experiment in
terms of the incidence of pre-neoplastic/neoplastic lesions
and/or overall Cdx2 staining (defined as the percentage of
Cdx2-positive cases amongst the different histological cat-
egories) were evaluated using the modified Kruskal-Wallis
non-parametric test for trend.
Differences were considered statistically significant when
p  < 0.05. All statistical analyses were performed with
STATA software (Stata Corporation, College Station,
Texas).
Results
Pathology (gross and histology)
Three main types of gross lesion were encountered, i.e.
reddened flat mucosa (at both gastric and esophageal
sites), ulcers, and protruding and/or nodular lesions. The
red mucosa was seen in the esophagus proximal to the
EGDA (proximal stomach and distal esophagus), whereas
both ulcers and protruding and/or nodular lesions were
always located close to the anastomosis. All gross abnor-
malities were sampled for histological assessment.
The histological lesions detected in the 3 groups of ani-
mals are summarized in Table 1 and Figure 1. All rats had
reflux (erosive or non-erosive) esophagitis proximal to the
Pathology findings of the esophageal cancer model Figure 1
Pathology findings of the esophageal cancer model. 
(A) Schematic illustration of the surgical intervention of the 
Kumagai-Hattori model (left) and representative macroscopic 
picture (right): unfixed esophagus, stomach and jejunum 
(excised en bloc) are opened through the dorsal wall 
(mucosal surface upward). (B-G) Histological findings 
observed (H&E staining): (B) anastomosis ulcer; (C) squa-
mous cell polypoid hyperplasia; (D) multilayered epithelium; 
(E) specialized columnar epithelium (intestinal metaplasia); (F) 
adenocarcinoma; (G) squamous cell cancer. (Original magnifi-
cations, 40×, 20× and 10×)Journal of Experimental & Clinical Cancer Research 2009, 28:108 http://www.jeccr.com/content/28/1/108
Page 4 of 6
(page number not for citation purposes)
anastomosis. Mucosal ulcers were located in the middle/
lower thirds of the esophagus in 15/22 (68.2%) animals
in Group A; 14/22 (63.6%) in Group B and 6/20 (30%)
in Group C. Regenerative/hyperplastic changes were also
identified (Group A = 10/22 [45.5%]; Group B = 8/22
[36.4%], Group C = 10/20 [50.0%]).
None of the animals in Group A revealed any intestinal
metaplasia (IM) and only 2 cases of MLE were seen (9.1%;
both located close to the EGDA). In Groups B and C, MLE
and IM were consistently identified and their prevalence
increased significantly with the time elapsing after the
operation (and with a similar prevalence of IM and MLE):
Group B = 9/22 (40.9%); Group C = 12/20 (60.0%) (test
for trend, p = 0.001).
Esophageal cancers were only documented histologically
more than 10 weeks after the operation (no cancers came
to light in Group A). In Group B, there were 10 esophageal
malignancies (45.5%; 8 esophageal Ac and 2 SSC); in
Group C, 9 cases of cancer were detected (45.0%; 7
esophageal Ac and 2 SSC). Eight cases of esophageal Ac
were located proximally to the cardia; both cases of SSC
developed in the middle-cervical esophagus. No neoplas-
tic vascular invasion or metastatic lesions (nodal or
extranodal) coexisted with the invasive cancers.
Cdx2 expression
The prevalence of Cdx2 nuclear expression in each of the
histological categories considered is shown in Table 1 and
Figure 2. Cdx2 was never expressed in native squamous
epithelia (including any non-ulcerative esophagitis) in
the upper third of the esophagus. Aberrant and inconsist-
ent Cdx2 nuclear expression was seen in the proliferative
compartment of the squamous mucosa, close to esopha-
geal ulcers and/or hyperplastic lesions (Group A = 4/22
[18.2%]; Group B = 6/22 [27.3%]; Group C = 8/20
[40.0%]).
In Groups B and C, intestinal metaplasia, multilayered
epithelium, and esophageal Ac all consistently showed
Cdx2 expression (Cdx2+ve cases: IM = 21/21; MLE = 21/
21; Esophageal Ac = 15/15). A trend towards higher levels
CDX2 immunohistochemical expression Figure 2
CDX2 immunohistochemical expression. (A) Cdx2 
aberrant nuclear expression in the basal layer of the squa-
mous native esophageal epithelium close to mucosal erosion. 
(B-C) Strong Cdx2 nuclear immunostain in multilayered epi-
thelium and intestinalized columnar epithelium. (D) Strong 
Cdx2 expression in intestinal metaplasia and aberrant Cdx2 
expression in basal squamous cells of native esophageal epi-
thelium. (E-F) Strong Cdx2 positivity in two cases of esopha-
geal adenocarcinoma. Note in E, the contrast with the Cdx2 
negative native esophageal epithelium. (Original magnifica-
tions, 40×, 20× and 10×)
Table 1: Histological findings and Cdx2 expression in the rat model of esophageal carcinogenesis.
Histology Cdx2 expression Group A 
(<10 weeks, n = 22)
Group B 
(10–30 weeks, n = 22)
Group C 
(>30 weeks, n = 20)
cases (%) cases (%) cases (%)





































Note: n = number of cases; wks = weeks; IM = intestinal metaplasia; MLE = multilayered epithelium; Ac = adenocarcinomas; SCC = squamous cell 
carcinomas.Journal of Experimental & Clinical Cancer Research 2009, 28:108 http://www.jeccr.com/content/28/1/108
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of overall Cdx2 expression was documented during the
course of the experiment (test for trend; p = 0.001). None
of the 4 cases of SCC showed Cdx2 staining.
Discussion
Gastro-esophageal reflux is generally considered the main
promoter of esophageal columnar metaplasia and adeno-
carcinoma.
Cdx2 is a transcription factor that regulates the expression
of differentiation-related molecules and it is specifically
involved in intestinal cells commitment. Based on this
rationale, Cdx2 immunohistochemical expression was
explored in a rat model of EGDA.
As in previous studies, de novo Cdx2 expression was docu-
mented in the whole spectrum of phenotypic changes
induced by experimental EGDA. The prevalence of Cdx2
expression increased significantly with time (i.e. the prev-
alence of IM and MLE was higher in Groups B and C than
in Group A), suggesting a time-dependent relationship
between the "chemical" injury and the severity of the
lesions.
Cdx2 expression in full-blown metaplastic transformation
was expected. This study, however, also showed that de
novo Cdx2 expression is an early event among the mor-
phological changes caused by the refluxate. The early
deregulation of Cdx2 expression has already been demon-
strated by Pera et al. [28], who described Cdx2 immunos-
taining in the basal cell layer close to esophageal ulcers 16
weeks after surgery. More recently, however, in a study
using a similar EGDA model, Xiaoxin Chen et al. [17] con-
sidered Cdx2 over-expression as a late marker of the meta-
plastic cascade.
Our study provides evidence that "protometaplastic"
changes (in both the squamous stem cell and MLE) could
be revealed by Cdx2 immunostaining even before the IM
becomes histologically assessable. It is worth noting that
MLE (which can also be a feature of normal rat mucosa)
might be considered as a "partially-committed" cell pop-
ulation, prone to a chimeric intestinal differentiation
under critical conditions (such as those produced by
EGDA). Such speculations might also apply to the stami-
nal cells compartment of the native esophageal mucosa:
in cultured esophageal epithelia, in fact, chemical injuries
(acid and/or bile components) may result in Cdx2 pro-
moter demethylation/activation [33]. These hypotheses
are further supported by the finding that no Cdx2 expres-
sion was detected in squamous epithelia (far from
esophageal ulcers/metaplastic changes), nor in any of the
4 cases of SCC.
Together with Cdx2, also other intestine-specific tran-
scription factors have been described as involved in Bar-
rett's epithelium development [34-36]. In a similar rat
model, Kazumori et al. [36] showed, that a de novo
expression of Cdx1 (another member of the caudal-
related homeobox gene family) significantly antecedes
Cdx2 expression [35,36]. Further studies are needed to
investigate on the interplay of these two genes in the mor-
phogenesis of Barrett's mucosa.
The SCC cases detected in this study prompts us to
hypothesize that the environmental conditions resulting
from EGDA may also result into the derangement of cell
regulatory mechanisms involving both multilayered and
squamous epithelia. Previous studies documented that
several transcription factors (p63, among others) are over-
expressed in squamous esophageal epithelia after EGDA.
Such an observation could explain, at least in part, the
high prevalence of SCC documented in this and other
studies.
Conclusion
In conclusion, the Kumagai-Hattori model of esophago-
gastroduodenal anastomosis (with gastric preservation) is
an useful in vivo model of esophageal carcinogenesis. Both
the stem cell compartment and the multilayered epithe-
lium are early involved in the metaplastic intestinaliza-
tion of the native esophageal mucosa.
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